Neutral Glycosphingolipids

α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor).

Glucosylsphingosine (lyso-Gb1) is a deacylated form of glucosylceramide with neurotoxicity and is also a noncompetitively inhibitor of glucocerebrosidase with a K_i value of 30 μM. Glucosylsphingosine is promising for research of Krabbe and Gaucher disease.

Galactosylceramide (GalC) is a galactosylceramide that has been implicated in many physiological and pathological phenomena. For example, important lysosomal storage disorders such as Gaucher disease (GD) and neurodegenerative diseases are characterized by GlcCer accumulation.

C6 NBD Glucosylceramide is a glucosylceramide fluorescent derivative (Ex=466 nm, Em=535 nm). C6 NBD Glucosylceramide can be used to study the metabolism and internalization of glucosylceramide and also for the determination of glucosyl ceramide synthase activity.

LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases.

C6 NBD Lactosylceramide is a derivative of lactosylceramides, and can be used in lactosylceramide synthase assay as a fluorescent acceptor substrate. C6 NBD Lactosylceramide can also be used in cancer research.

C22 Glucosylceramide (d18:1/22:0)-d₄ is deuterium labeled C22 Glucosylceramide (d18:1/22:0) (HY-164236). C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields.

C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields.

C6 NBD galactosylceramide is an active derivative of galactosylceramide that is tagged with fluorescent C6 nitrobenzoxadiazole (C6 NBD). C6 NBD galactosylceramide can be used as a substrate for neutral β-glycosylceramidase (GCase) to study intracellular localization and metabolism of galactosylceramide (Ex=nm, Em=525).

D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl (β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand with immunostimulatory activity. D-Glucosyl-β-1,1′-N-palmitoylsphingosine binds to and activates macrophage-inducible C-type lectin (Mincle). D-Glucosyl-β-1,1′-N-palmitoylsphingosine is applicable to the research of immune system diseases.

Glucosylceramide (Glucocerebrosides) (gaucher's spleen) is a glycosphingolipid and primary substrate of acid β-glycosidase, suppresses tyrosine phosphorylation of insulin receptor and IRS-1, disrupts insulin signaling cascade and triggers pancreatic β-cell dysfunction. Glucosylceramide (Gaucher's spleen) accumulates in rodents and induces obesity and insulin resistance, restores systemic glucose homeostasis and insulin sensitivity when synthesis is suppressed. Glucosylceramide (Gaucher's spleen) accumulates in the brain of chronic neuronopathic Gaucher disease mice with age and can be applied for research on insulin resistance, type 2 diabetes mellitus and chronic neuronopathic Gaucher disease.

Glucosylceramide, plant (GluCer (Soy)) is an orally active, plant-derived glucosylceramide. Glucosylceramide, plant inhibits lipopolysaccharide-induced cytokine production and Apoptosis. Glucosylceramide, plant suppresses DSS-induced body weight loss, colonic crypt damage and intestinal inflammation in mice. Glucosylceramide, plant can be used in research related to inflammatory bowel disease and colon cancer.

Cerebroside B, a sphingolipid compound, is a non-racespecific elicitor, which elicits defense responses in rice.

C20 Glucosyl(β) ceramide (d18:1/20:0) is a β-glucosyl ceramide.

Trihexosylceramide (d18:1/12:0) is a glycosphingolipid and mood-related compound. Trihexosylceramide (d18:1/12:0) is characterized by elevated serum levels in Mus musculus fed a high-fat diet, and its levels are positively correlated with mood Z-scores. Accumulation of Trihexosylceramide (d18:1/12:0) in tissues is considered the etiology of angiokeratoma corporis diffusum. Trihexosylceramide (d18:1/12:0) can be used in studies related to high-fat diet-induced mood disorders.\n

C17 Globotriaosylceramide (d18:1/17:0) is a sphygosine lipid that can be used to quantify Globotriaosylceramide in plasma and urine of patients with Fabry disease by gas chromatography-mass spectrometry (GC-MS).

C18 Glucosyl(ß) ceramide-d₅ is deuterium labeled C18 Glucosyl(ß) ceramide.

C22 Galactosylceramide is a sphingolipid present in the central nervous system, exhibiting elevated levels in the spinal cord of mice on a methionine-restricted diet, while not affecting the brain or liver; furthermore, it has been identified in the postmortem hippocampus of Alzheimer's disease patients.

C16 Galactosylceramide is a sphingolipid compound. C16 Galactosylceramide participates in the physiological processes of lipid metabolism and immune regulation in cells. C16 Galactosylceramide can be used in the study of diabetes.

Gb3 (d18:1/16:0) (Compound 1) is the P^k antigen of the P blood group system. Gb3 (d18:1/16:0) acts as a cell surface receptor. Gb3 (d18:1/16:0) is used for research on Burkitt's lymphoma, teratocarcinoma, embryonal carcinoma, and Fabry's disease.